JAK2-binding Long Noncoding RNA Promotes Breast Cancer Brain Metastasis
Shouyu Wang,Ke Liang,Qingsong Hu,Ping Li,Jian Song,Yuedong Yang,Jun Yao,Lingegowda Selanere Mangala,Chunlai Li,Wenhao Yang,Peter K. Park,David H. Hawke,Jianwei Zhou,Yan Zhou,Weiya Xia,Mien-Chie Hung,Jeffrey R. Marks,Gary E. Gallick,Gabriel Lopez-Berestein,Elsa R. Flores,Anil K. Sood,Suyun Huang,Dihua Yu,Liuqing Yang,Chunru Lin
DOI: https://doi.org/10.1172/jci91553
IF: 19.456
2017-01-01
Journal of Clinical Investigation
Abstract:Conventional therapies for breast cancer brain metastases (BCBMs) have been largely ineffective because of chemoresistance and impermeability of the blood-brain barrier. A comprehensive understanding of the underlying mechanism that allows breast cancer cells to infiltrate the brain is necessary to circumvent treatment resistance of BCBMs. Here, we determined that expression of a long noncoding RNA (lncRNA) that we have named lncRNA associated with BCBM (Lnc-BM) is prognostic of the progression of brain metastasis in breast cancer patients. In preclinical murine models, elevated Lnc-BM expression drove BCBM, while depletion of Lnc-BM with nanoparticle-encapsulated siRNAs effectively treated BCBM. Lnc-BM increased JAK2 kinase activity to mediate oncostatin M-and IL-6-triggered STAT3 phosphorylation. In breast cancer cells, Lnc-BM promoted STAT3-dependent expression of ICAM1 and CCL2, which mediated vascular co-option and recruitment of macrophages in the brain, respectively. Recruited macrophages in turn produced oncostatin M and IL-6, thereby further activating the Lnc-BM/JAK2/STAT3 pathway and enhancing BCBM. Collectively, our results show that Lnc-BM and JAK2 promote BCBMs by mediating communication between breast cancer cells and the brain microenvironment. Moreover, these results suggest targeting Lnc-BM as a potential strategy for fighting this difficult disease.